RxDoctor Payments Data

Tiffany Williams

Family · Bluffton, SCNPI 1972955763

Payments from drug & device makers

$2,343in general payments, 2019–2025

Across 108 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$424
  • Amgen$369
  • OPKO Pharmaceuticals, LLC$301
  • Novartis$209
  • AstraZeneca$182
  • Ardelyx, Inc.$166
  • plus $692 from 12 others

What the payments were for

  • Food & beverage$2,04287%
  • Education$30113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,343 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol68$57,891
KerendiaFinerenone36$41,061
RybelsusSemaglutide23$36,595
RayaldeeCalcifediol23$32,403
JardianceEmpagliflozin23$18,124
OzempicSemaglutide16$17,356
LokelmaSodium Zirconium Cyclosilicate15$11,628
JanuviaSitagliptin Phosphate12$9,068
ProsolParenteral Amino Acid 20% No.142$7,164
Xigduo XrDapaglifloz Propaned/Metformin11$6,509
Telmisartan-AmlodipineTelmisartan/Amlodipine42$5,625
Sevelamer Carbonate11$3,418
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med53$2,197
Calcium Acetate16$1,838
Telmisartan89$1,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$182$69,51883 claims
Novo NordiskRybelsus, Ozempic$42$53,95139 claims
BayerKerendia$133$41,06136 claims
OPKO Pharmaceuticals, LLCRayaldee$301$32,40323 claims
ANI Pharmaceuticals, Inc.Valsartan$66$1,34865 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.

Other family in Bluffton

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →